Elliott B. Grossbard

3.3k total citations
32 papers, 2.1k citations indexed

About

Elliott B. Grossbard is a scholar working on Hematology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Elliott B. Grossbard has authored 32 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 12 papers in Immunology and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Elliott B. Grossbard's work include Mast cells and histamine (10 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Elliott B. Grossbard is often cited by papers focused on Mast cells and histamine (10 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Elliott B. Grossbard collaborates with scholars based in United States, United Kingdom and Netherlands. Elliott B. Grossbard's co-authors include Michael E. Weinblatt, Arthur Kavanaugh, Mark C. Genovese, Daniel B. Magilavy, Donald G. Payan, Esteban S. Masuda, Muhammad Baluom, Eli O. Meltzer, Robert Berkowitz and Polly Pine and has published in prestigious journals such as New England Journal of Medicine, Blood and The Journal of Immunology.

In The Last Decade

Elliott B. Grossbard

31 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elliott B. Grossbard United States	22	823	522	493	465	374	32	2.1k
Katsuyasu Saigo Japan	20	346 0.4×	247 0.5×	609 1.2×	521 1.1×	238 0.6×	106	1.8k
Jonathan S. Coblyn United States	21	443 0.5×	368 0.7×	466 0.9×	1.2k 2.6×	265 0.7×	34	2.1k
Peter C. Harpel United States	25	523 0.6×	382 0.7×	964 2.0×	537 1.2×	140 0.4×	46	2.8k
J. D. Macfarlane Netherlands	12	875 1.1×	287 0.5×	731 1.5×	1.7k 3.7×	502 1.3×	39	3.0k
Jay N. Lozier United States	27	371 0.5×	397 0.8×	1.1k 2.1×	212 0.5×	186 0.5×	65	2.6k
Rolf Rau Germany	23	770 0.9×	394 0.8×	963 2.0×	2.4k 5.2×	285 0.8×	39	3.3k
K.A. Rickard Australia	19	393 0.5×	211 0.4×	881 1.8×	387 0.8×	222 0.6×	68	1.8k
Piotr Adrian Klimiuk Poland	28	995 1.2×	148 0.3×	270 0.5×	1.1k 2.3×	436 1.2×	77	2.5k
H. Terence Cook United Kingdom	22	824 1.0×	161 0.3×	236 0.5×	704 1.5×	143 0.4×	45	2.3k
Yoshitaka Morita Japan	26	1.0k 1.2×	95 0.2×	296 0.6×	775 1.7×	168 0.4×	105	2.7k

Countries citing papers authored by Elliott B. Grossbard

Since Specialization

Citations

This map shows the geographic impact of Elliott B. Grossbard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elliott B. Grossbard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elliott B. Grossbard more than expected).

Fields of papers citing papers by Elliott B. Grossbard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elliott B. Grossbard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elliott B. Grossbard. The network helps show where Elliott B. Grossbard may publish in the future.

Co-authorship network of co-authors of Elliott B. Grossbard

This figure shows the co-authorship network connecting the top 25 collaborators of Elliott B. Grossbard. A scholar is included among the top collaborators of Elliott B. Grossbard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elliott B. Grossbard. Elliott B. Grossbard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Martin, Paul, Michael Gillen, David Millson, et al.. (2016). Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies. Drugs in R&D. 16(1). 81–92. 15 indexed citations

Weinblatt, Michael E., Arthur Kavanaugh, Mark C. Genovese, et al.. (2013). Effects of Fostamatinib (R788), an Oral Spleen Tyrosine Kinase Inhibitor, on Health-related Quality of Life in Patients with Active Rheumatoid Arthritis: Analyses of Patient-reported Outcomes from a Randomized, Double-blind, Placebo-controlled Trial. The Journal of Rheumatology. 40(4). 369–378. 33 indexed citations

Kavanaugh, Arthur, Michael E. Weinblatt, Mark C. Genovese, et al.. (2011). Longer-term safety of fostamatinib (R788) in patients with rheumatoid arthritis. Analysis of clinical trial data from up to 2 years of exposure. Research Explorer (The University of Manchester). 7 indexed citations

Baluom, Muhammad, Emil Samara, Elliott B. Grossbard, & David T. W. Lau. (2011). Fostamatinib, a Syk-Kinase Inhibitor, Does Not Affect Methotrexate Pharmacokinetics in Patients With Rheumatoid Arthritis. The Journal of Clinical Pharmacology. 51(9). 1310–1318. 19 indexed citations

Genovese, Mark C., Arthur Kavanaugh, Michael E. Weinblatt, et al.. (2010). An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three‐month randomized, placebo‐controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis & Rheumatism. 63(2). 337–345. 167 indexed citations

Chang, Betty, Feifei Zhao, Xiaodong He, et al.. (2009). JAK3 Inhibition Significantly Attenuates Psoriasiform Skin Inflammation in CD18 Mutant PL/J Mice. The Journal of Immunology. 183(3). 2183–2192. 56 indexed citations

Schroeder, Raymond E., Elizabeth V. Weaver, Vanessa Taylor, et al.. (2008). Developmental toxicity associated with receptor tyrosine kinase Ret inhibition in reproductive toxicity testing. Birth Defects Research Part A Clinical and Molecular Teratology. 85(2). 130–136. 23 indexed citations

Bahjat, Frances Rena, Polly Pine, Andrea Reitsma, et al.. (2008). An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis & Rheumatism. 58(5). 1433–1444. 137 indexed citations

Weinblatt, Michael E., Arthur Kavanaugh, Rubén Burgos‐Vargas, et al.. (2008). Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve‐week, randomized, placebo‐controlled trial. Arthritis & Rheumatism. 58(11). 3309–3318. 267 indexed citations

10.

Masuda, Esteban S., Elliott B. Grossbard, & Donald G. Payan. (2007). Reply. Journal of Allergy and Clinical Immunology. 119(5). 1277–1279. 1 indexed citations

11.

Zhu, Yanhong, Ellen Herlaar, Esteban S. Masuda, et al.. (2007). Immunotoxicity assessment for the novel Spleen tyrosine kinase inhibitor R406. Toxicology and Applied Pharmacology. 221(3). 268–277. 35 indexed citations

12.

Meltzer, Eli O., Robert Berkowitz, & Elliott B. Grossbard. (2005). An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. Journal of Allergy and Clinical Immunology. 115(4). 791–796. 116 indexed citations

13.

Clemens, L. Edward, et al.. (1998). Pharmacokinetics and Biological Actions of Subcutaneously Administered Human Brain Natriuretic Peptide. Journal of Pharmacology and Experimental Therapeutics. 287(1). 67–71. 13 indexed citations

14.

Hobbs, Robert E., et al.. (1996). Hemodynamic Effects of a Single Intravenous Injection of Synthetic Human Brain Natriuretic Peptide in Patients With Heart Failure Secondary to Ischemic or Idiopathic Dilated Cardiomyopathy**This study was supported by a grant from Scios Nova, Inc., Mountain View, California.. The American Journal of Cardiology. 78(8). 896–901. 74 indexed citations

15.

Goodin, Thomas, et al.. (1994). A perfluorochemical emulsion for prehospital resuscitation of experimental hemorrhagic shock. Critical Care Medicine. 22(4). 680–689. 23 indexed citations

16.

Smalling, Richard W., Richard R. Schumacher, Douglas C. Morris, et al.. (1990). Improved infarct-related arterial patency after high dose, weight-adjusted, rapid infusion of tissue-type plasminogen activator in myocardial infarction: Results of a multicenter randomized trial of two dosage regimens. Journal of the American College of Cardiology. 15(5). 915–921. 58 indexed citations

17.

Goldhaber, Samuel Z., Michael F. Meyerovitz, John E. Markis, et al.. (1987). Thrombolytic therapy of acute pulmonary embolism: Current status and future potential. Journal of the American College of Cardiology. 10(5). 96B–104B. 45 indexed citations

18.

Topol, Eric J., Douglas C. Morris, Richard W. Smalling, et al.. (1987). A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (activase) in acute myocardial infarction. Journal of the American College of Cardiology. 9(6). 1205–1213. 148 indexed citations

19.

Grossbard, Elliott B.. (1987). Recombinant Tissue Plasminogen Activator: A Brief Review. Pharmaceutical Research. 4(5). 375–378. 37 indexed citations

20.

Topol, Eric J., Allen Ciuffo, Thomas A. Pearson, et al.. (1985). Thrombolysis with recombinant tissue plasminogen activator in atherosclerotic thrombotic occlusion. Journal of the American College of Cardiology. 5(1). 85–91. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact